Ceftaroline: Difference between revisions
(Created page with "==General== *Type: *Dosage Forms: *Common Trade Names: ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== *Pregnancy Rating: *Lac...") |
ClaireLewis (talk | contribs) No edit summary |
||
(13 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: | *Type: Antibiotic, Cephalosporin (fifth generation) | ||
*Dosage Forms: | *Dosage Forms: IV | ||
*Common Trade Names: | *Common Trade Names: Teflaro | ||
==Adult Dosing== | ==Adult Dosing== | ||
* Pneumonia, Community-acquired: IV: 600 mg every 12 hours for 5 to 7 days | |||
* Skin and skin structure infection: IV: 600 mg every 12 hours for 5 to 14 days | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
* Cystic Fibrosis pulmonary exacerbation, MRSA: | |||
** Children ≥ 6 years old - IV 15 mg/kg/dose every 8 hours (max dose 600 mg/dose) | |||
* Pneumonia, community acquired: | |||
** ≥ 2 months - < 2 years age - IV 8 mg/kg/dose every 8 hours for 5-14 days | |||
** ≥ 2 years - < 18 years | |||
*** ≤ 33 kg: IV 12 mg/kg/dose every 8 hours for 5-14 days | |||
*** > 33 kg: IV 400 mg every 8 hours OR 600 mg every 12 hours for 5-14 days | |||
* Skin and skin structure infection: | |||
** ≥ 2 months - < 2 years age - IV 8 mg/kg/dose every 8 hours | |||
** ≥ 2 years - < 18 years | |||
*** ≤ 33 kg: IV 12 mg/kg/dose every 8 hours | |||
*** > 33 kg: IV 400 mg every 8 hours OR 600 mg every 12 hours | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | ||
** Adverse events have been observed in animal studies | |||
*Lactation: | *Lactation: | ||
** Unknown if excreted in breast milk. Manufacturer recommends to use caution when giving to nursing women. | |||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult | ||
*** CrCl > 50 mL/minute: No dosage adjustment necessary | |||
*** CrCl > 30 to ≤ 50 mL/minute: 400 mg every 12 hours | |||
*** CrCl ≥ 15 to ≤ 30 mL/minute: 300 mg every 12 hours | |||
*** CrCl < 15 mL/minute: 200 mg every 12 hours | |||
*** ESRD patients on hemodialysis: 200 mg every 12 hours; dose given after hemodialysis on dialysis days | |||
**Pediatric | **Pediatric | ||
*** ≥ 2 months to < 18 years of age | |||
**** CrCl > 50 mL/minute/1.73 m²: No adjustment necessary | |||
**** CrCl ≤ 50 mL/minute/1.73 m²: Insufficient data, use with caution, dosing adjustment may be necessary | |||
*** ≥ 18 years of age - same as adult dosing | |||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult | **Adult | ||
*** No dosage adjustment in manufacturer's labeling. Has not been studied. | |||
**Pediatric | **Pediatric | ||
*** No dosage adjustment in manufacturer's labeling. Has not been studied. | |||
==Contraindications== | ==Contraindications== | ||
Line 23: | Line 52: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*[[C. diff]] | |||
*Elevated ALT/SGPT, hepatitis | |||
*[[Anaphylaxis]], hypersensitivity reaction | |||
*[[Seizure]] | |||
*[[Renal failure]] | |||
===Common=== | ===Common=== | ||
*[[Nausea/vomiting]], [[diarrhea]] | |||
*[[Rash]] | |||
*[[Fever]] | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: | ||
** 1.6 ± 0.38 hours (single dose), 2.66 ± 0.4 hours (multiple doses) | |||
*Metabolism: | *Metabolism: | ||
*Excretion: | *Excretion: | ||
** Urine 88%, Feces 6% | |||
*Mechanism of Action: | *Mechanism of Action: | ||
** Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins | |||
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ||
Line 155: | Line 195: | ||
==See Also== | ==See Also== | ||
== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | |||
Ceftaroline: Drug information. UpToDate. www.uptodate.com. Accessed April 1, 2019. |
Revision as of 09:01, 27 May 2019
General
- Type: Antibiotic, Cephalosporin (fifth generation)
- Dosage Forms: IV
- Common Trade Names: Teflaro
Adult Dosing
- Pneumonia, Community-acquired: IV: 600 mg every 12 hours for 5 to 7 days
- Skin and skin structure infection: IV: 600 mg every 12 hours for 5 to 14 days
Pediatric Dosing
- Cystic Fibrosis pulmonary exacerbation, MRSA:
- Children ≥ 6 years old - IV 15 mg/kg/dose every 8 hours (max dose 600 mg/dose)
- Pneumonia, community acquired:
- ≥ 2 months - < 2 years age - IV 8 mg/kg/dose every 8 hours for 5-14 days
- ≥ 2 years - < 18 years
- ≤ 33 kg: IV 12 mg/kg/dose every 8 hours for 5-14 days
- > 33 kg: IV 400 mg every 8 hours OR 600 mg every 12 hours for 5-14 days
- Skin and skin structure infection:
- ≥ 2 months - < 2 years age - IV 8 mg/kg/dose every 8 hours
- ≥ 2 years - < 18 years
- ≤ 33 kg: IV 12 mg/kg/dose every 8 hours
- > 33 kg: IV 400 mg every 8 hours OR 600 mg every 12 hours
Special Populations
- Pregnancy Rating:
- Adverse events have been observed in animal studies
- Lactation:
- Unknown if excreted in breast milk. Manufacturer recommends to use caution when giving to nursing women.
- Renal Dosing
- Adult
- CrCl > 50 mL/minute: No dosage adjustment necessary
- CrCl > 30 to ≤ 50 mL/minute: 400 mg every 12 hours
- CrCl ≥ 15 to ≤ 30 mL/minute: 300 mg every 12 hours
- CrCl < 15 mL/minute: 200 mg every 12 hours
- ESRD patients on hemodialysis: 200 mg every 12 hours; dose given after hemodialysis on dialysis days
- Pediatric
- ≥ 2 months to < 18 years of age
- CrCl > 50 mL/minute/1.73 m²: No adjustment necessary
- CrCl ≤ 50 mL/minute/1.73 m²: Insufficient data, use with caution, dosing adjustment may be necessary
- ≥ 18 years of age - same as adult dosing
- ≥ 2 months to < 18 years of age
- Adult
- Hepatic Dosing
- Adult
- No dosage adjustment in manufacturer's labeling. Has not been studied.
- Pediatric
- No dosage adjustment in manufacturer's labeling. Has not been studied.
- Adult
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- C. diff
- Elevated ALT/SGPT, hepatitis
- Anaphylaxis, hypersensitivity reaction
- Seizure
- Renal failure
Common
Pharmacology
- Half-life:
- 1.6 ± 0.38 hours (single dose), 2.66 ± 0.4 hours (multiple doses)
- Metabolism:
- Excretion:
- Urine 88%, Feces 6%
- Mechanism of Action:
- Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014
Ceftaroline: Drug information. UpToDate. www.uptodate.com. Accessed April 1, 2019.